- PR Newswire•7 days agoLexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes
THE WOODLANDS, Texas, Jan. 9, 2016 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the commencement of dosing in a Phase 1 clinical trial of LX2761, an orally-delivered small ...
- PR Newswire•11 days ago
THE WOODLANDS, Texas, Jan. 5, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 10:30 a.m. Pacific Time in San Francisco. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
- Investopedia•11 days ago
Investopedia looks at biotech companies that are awaiting FDA decisions in early 2017.
LXRX : Summary for Lexicon Pharmaceuticals, Inc. - Yahoo Finance
Lexicon Pharmaceuticals, Inc. (LXRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||13.82 x 100|
|Ask||16.88 x 100|
|Day's Range||14.38 - 14.99|
|52 Week Range||7.65 - 19.62|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-68.60|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|